Using a high-content screening of small compounds and FDA-approved drug libraries, we identified the anti-cancer drug Sorafenib tosylate as a potent inhibitor of TNF-dependent necroptosis.

Orphan Drug Sorafenib Tosylate (Nexavar) for Hepatocellular Carcinoma On April 26, the FDA approved orphan drug status for sorafenib tosylate ( Nexavar tablets, made by Onyx Pharmaceuticals ...

Sorafenib Tosylate (Nexavar) for Advanced Renal Cell Carcinoma in EU On July 23, the European Commission approved sorafenib tosylate ( Nexavar tablets, made by Onyx Pharmaceuticals, Inc ...

Methods: Eight-week old BALB/cA male mice were used in in vivo studies. Sorafenib tosylate was administered per os once daily at a dose of 150 mg/kg body weight. Control mice were given vehicle alone.

Interim results from a randomized clinical trial for patients with desmoid tumors or aggressive fibromatosis (DT/DF) show that the drug sorafenib tosylate (Nexavar) extended progression-free survival ...